Category: Cardiovascular

A population-based, retrospective study looked at the associations between cannabis use and effects on heart health. In a study published in the journal Addiction in September 2023, researchers used compiled data from five Canadian health databases to examine the connections between cannabis use disorder (CUD) and cardiovascular disease (CVD) (1). The purpose of the study, researchers explained, was to address the lack of conclusive and recent literature on the topic by measuring the association between CUD and CVD (1). The study examined data from 2012 to 2019 on a total of 59,528 individuals, half of whom had a CUD diagnosis (1). In reportedly one of the first Canadian studies looking into these associations, researchers did not find a causal link between CUD and CVD, but did conclude that compared to individuals without CUD, “Canadian adults with cannabis use disorder appear to have an approximately 60% higher risk of experiencing incident adverse cardiovascular disease events,” (1). Advertisement Researchers explained the significance of their findings for patients (1). “Importantly, this evidence suggests that cannabis use may place a healthier population at increased risk of major cardiovascular events,” the Conclusion stated (1). “As a result, our study points to the importance of educating our patients about the potential risks associated with cannabis use and CUD.” The study’s lead researcher, Anees Bahji, MD, commented on the implications of the study (2). “The relationship between cannabis use and cardiovascular events is complex and may also be influenced by factors such as the method of cannabis consumption, the presence of other co-occurring health conditions, and individual variations in response to cannabis,” Dr. Bahji said (2). “Further research is needed to better understand these mechanisms and the overall impact on cardiovascular health.” Peter Grinspoon, MD, primary care physician at Massachusetts General Hospital and cannabis specialist also commented on the findings (2). “The presence of cannabis use disorder isn’t very accurate in helping us to determine anything,” Dr. Grinspoon said of this study (2). “That said, if you take too high a dosage of cannabis, it can cause anxiety which, in turn, can trigger an arrhythmia [an irregular heartbeat] or possibly a coronary event, so, inpatients with a history of coronary disease, particularly recent, unstable coronary disease, or with a history of arrhythmia, I treat very carefully if at all with medicinal cannabis.” Hear what Dr. Grinspoon has to say on medical cannabis in our Cannabis Science and Technology in-depth interview. References Bahji, A, Hathaway, J, Adams, D, Crockford, D, Edelman, EJ, Stein, MD, et al. Cannabis use disorder and adverse cardiovascular outcomes: A population-based retrospective cohort analysis of adults from Alberta, Canada. Addiction. 2023. https://doi.org/10.1111/add.16337 Reinberg, S. Heavy marijuana use may harm the heart – U.S. news & world report https://www.usnews.com/news/health-news/articles/2023-09-28/heavy-marijuana-use-may-harm-the-heart (accessed Oct 12, 2023).

Deep sleep with auditory stimulation poses benefits to the heart, specifically the left ventricle, causing it to contract and relax more vigorously, according to the results of a study from the University of Zurich. Investigators noted that blood is pumped more efficiently through the circulatory system, which will benefit most organs, extremities, and the brain.1 ryanking999 – stock.adobe.com In the study (NCT04166916), published in the European Heart Journal, investigators used echocardiography, or cardiac ultrasound examinations, to show how the left ventricle changes after a auditory stimulation. According to a statement, this is the first time that research has shown an increase in brain waves during deep sleep that improved cardiac function.1 “We were expecting that stimulation with tones during deep sleep would impact the cardiovascular system, but the fact that this effect was so clearly measurable after just 1 night of stimulation surprised us,” Caroline Lustenberger, PhD, Swiss National Science Foundation Ambizione Fellow at the Neural Control of Movement Lab at ETH Zurich, said in the statement.1 There were 18 individuals included in the study, who were non-smokers and had no cardiovascular disease, sleep disorders or comorbidities, or significant concomitant diseases, according to the study authors. They spent 3 non-consecutive nights in a sleep laboratory, in which investigators stimulated the individuals with sounds on 2 nights.1,2 The investigators continuously measured the individual’s brain activity, blood pressure, and heart activity during sleep. The measurements were simultaneously uploaded into a computer to analyze the data.1 When the individual fell into deep sleep, a series of brief tones at frequencies known as pink noise played. The series was 10 seconds of pink noise, followed by 10 seconds of silence, then repeated. Investigators monitored whether the sound enhanced deep sleep and whether it influenced the individual’s heart rate and blood pressure. In the morning, the investigators examined the cardiac function of the individual.1 The study authors reported that the pink noise stimulation during sleep significantly and globally enhanced slow waves, and influenced cardiovascular functions. There were no significant differences in the condition of absolute systolic blood pressure, according to the results; however, after corrections made to baseline data, investigators found a small, but consistent, increase in relative systolic blood pressure.2 Furthermore, the study authors observed a significant increase in the left ventricular, with a significant increase in left ventricular ejection fraction and a significant decrease in the left ventricular E/e′ ratio. They determined that the results indicate improvements in left ventricular systolic and diastolic functions for the pink noise stimulation. Additionally, the blood biomarkers and carotid-femoral pulse wave velocity showed no significant effect on the stimulation overnight.2 “Despite the relatively small group of subjects, the results are significant. We were also able to reproduce the results on 2 separate nights, which in statistical terms makes them very strong,” Lustenberger said in the statement.1 She added that future studies should include those who are female due to sex differences in sleep and cardiovascular health, especially because the menstrual cycle and menopause have major effects on sleep.1 Investigators will also look to research more powerful stimulation methods to determine the impact on the cardiovascular system.1 References Increased deep sleep benefits your heart. News release. EurekAlert. October 5, 2023. Accessed October 13, 2023. https://www.eurekalert.org/news-releases/1003820 Huwiler S, Carro-Domínguez M, Stich FM, Sala R, et al. Auditory stimulation of sleep slow waves enhances left ventricular function in humans. Eur Heart J. 2023;ehad630. doi:10.1093/eurheartj/ehad630

Illustration Photo: Ponomariova_Maria/Getty Images Projections indicate that cardiovascular disease and depression will top the list of global disability causes soon, so the urgency for targeted interventions is evident, writes Dr Mosima Mabunda. A clinical diagnosis of depression is far more complex than mental distress. It is a chronic condition that manifests as unshakeable feelings of sadness, hopelessness, and a lack of interest in activities. The troubling truth is that it’s not just a mental issue. It impacts people’s physical health too. In many cases, depression can lead to poor eating and sleeping habits and a lack of motivation to do physical activity. Health practitioners and employers are seeing an increased need to raise awareness around improving mental health. This is also the purpose of Mental Health Awareness Month and World Mental Health Day, which was on 10 October 2023. I am writing this looking at the sobering statistics that 280 million people worldwide live with depression and that research shows a relationship between depression and certain diseases, specifically heart-related conditions. Projections indicate that cardiovascular disease and depression will top the list of global disability causes soon, so the urgency for targeted interventions is evident. What is the link between depression and heart health? I spoke to Prof Renata Schoeman, a general psychiatrist and associate professor in Leadership at the University of Stellenbosch Business School, about this. She says studies show patients with major depressive disorder have a 64% higher risk of eventually developing coronary heart disease. The link between coronary events and depression is also distinct, with up to 40% of patients meeting the criteria for major depression after suffering from a cardiac event. In outpatient clinics, the rate of depression is 30% in patients with coronary heart disease and up to a staggering 50% in patients who are hospitalised for coronary artery bypass surgery. In those who have recently suffered a heart attack, up to 74% are diagnosed with depression. The relationship between cardiovascular diseases and depression is complex, with numerous factors at play. What is clear is that people with depression are at a greater risk of developing heart disease. Professor Schoeman says major depression causes psychological stress that can lead to deregulation in the sympathetic nervous system and endocrine system, which regulate our stress response. These factors, in turn, can lead to an increase in blood pressure and inflammation, among other factors — all risks for developing heart disease. Professor Schoeman says that, unfortunately, people with major depressive disorder often have increased rates of smoking, alcohol intake, physical inactivity, and obesity. She always encourages patients to take responsibility for lifestyle changes and comply with treatment to improve health outcomes. Her view on the importance of lifestyle changes, looking at depression, is supported by findings of a Vitality study by researchers from Harvard T.H. Chan School of Public Health and the University of Cape Town. It found that one in five cases of depression in women could be prevented if physical activity increased by walking just an extra 5,000 steps a week. In addition, moderate to severe symptoms of depression are 4.9 times proportionally lower when levels of cardiorespiratory fitness are higher. The solutions Where do we start? Screening people is a critical step. Professor Schoeman says there is a need for healthcare professionals to screen for depression in cases of heart disease and for mental healthcare providers to screen patients with depression for other illnesses. Along with adhering to prescribed medicine interventions, adapting lifestyle behaviours is an important part of treating these conditions. Things like not smoking, following a healthy diet, being active, losing weight, managing diabetes, hypertension, high cholesterol and adhering to recommendations from rehabilitation programs are important. We have seen that having regular health screenings is an effective way to manage health. This insightful snapshot of their health facilitates early detection of risk factors for cardiovascular disease and ways to proactively manage these risks. Assessment is crucial, particularly for those diagnosed with chronic diseases. We have seen that people who complete programs validate depression screenings and are three times more likely to seek mental health support. Professor Schoeman stressed that we need to be more aware of the interaction between depression and heart disease. Early identification and intervention are crucial. Being aware of a mental health or heart condition means people have an opportunity to adopt behaviour that supports good mental and physical health. Dr Mosima Mabunda is the Head of Wellness at Discovery Vitality. Disclaimer: News24 encourages freedom of speech and the expression of diverse views. The views of columnists published on News24 are therefore their own and do not necessarily represent the views of News24.

Adults with moderate to severe depression were found to have a higher all-cause risk of ischemic heart and cardiovascular disease (CVD) mortality than adults without depression, according to a prospective cohort study published in JAMA Network Open. “Taken together with the body of literature on associations between depression and CVD mortality, these findings can support public health efforts to develop a comprehensive, nationwide strategy to improve well-being, including both mental and cardiovascular health,” study authors noted. The research, conducted between 2005 and 2019, included 23,694 participants, with a mean age of 44.7 years. Depressive symptoms were categorized as none or minimal, mild, and moderate to severe using Patient Health Questionnaire-9 (PHQ-9) scores. Participants were sourced with the National Health and Nutrition Examination Survey 2005 to 2018 and participant data was linked with the National Death Index through the year 2019 for adults 20 years and older. Data were analyzed between March 1, 2023, and May 26, 2023. Participants with mild depressive symptoms exhibited a 35% higher risk of all-cause mortality and a 49% higher risk of CVD mortality compared to those without depressive symptoms. This risk increased to 62% higher all-cause and 79% higher CVD for individuals with moderate to severe depressive symptoms. The association was also explored in relation to ischemic heart disease mortality, where individuals with moderate to severe depressive symptoms faced a 121% higher risk. Lifestyle factors explained around 11% to 16% of the link between depression and mortality. Notably, feelings of fatigue, poor appetite or overeating, and disinterest in activities were independently associated with both all-cause and CVD mortality. Authors noted that depressive symptoms were only measured at baseline, so there is no account for how depressive symptoms changed over time, which may have limited the results. ReferenceZhang Z, Jackson SD, Gillespie C, et al. Depressive symptoms and mortality among US adults. JAMA Netw Open. 2023;6(10). doi:10.1001/jamanetworkopen.2023.37011

1:14 Obesity and cardiovascular risk 3:28 Topline findings for semaglutide in the SELECT trial 7:15 CV risk reduction with semaglutide 8:54 Perspectives on cost-benefit for GLP-1 in obesity 14:14 Outcomes from STEP HFpEF trial 16:44 Considerations for using GLP-1 agonists 20:54 Need to address inequity in access to obesity medications 26:44 Investigational therapies for obesity with potential for CV benefits 30:00 Combination therapy for obesity and CV risk

Regular adherence to antimalarial medication among individuals with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) has been shown to significantly lower cardiovascular risk over time, according to study results published in Arthritis Care & Research. Chronic inflammatory autoimmune diseases such as RA and SLE are associated with an increased risk for inflammatory complications, notably, cardiovascular disease. Long term maintenance of these conditions consists mainly of treatment with antimalarial medications. The added lipid lowering, anti-inflammatory, and hypoglycemic effects of these drugs can further attenuate cardiovascular risk. To quantify this benefit, researchers investigated cardiovascular outcomes among patients with RA and SLE in relation to antimalarial adherence. A retrospective, longitudinal cohort study was conducted in British Columbia, Canada. Adult patients aged at least 18 years with newly diagnosed RA or SLE who were prescribed antimalarial medications at least once without experiencing a cardiovascular event were included in the analysis. Population Data BC (PopData), an electronic medical tracking record for all residents, was used to collect patient data on outpatient visits, hospitalizations, demographic information, and comprehensive information on prescription medications. Individuals were tracked for medical adherence based on the first day receiving an antimalarial drug and at 90-day interval windows thereafter. Adherence was calculated as a proportion of time when medication was taken as prescribed. The protective effect of antimalarial was found to be lost when adhering to less than 90% of the prescribed doses, and a greater degree of protection was observed in older patients. The composite primary study outcome was incident cardiovascular events, including myocardial infarction (MI), ischemic stroke, and venous thromboembolism (VTE). A total of 16,538 individuals treated with antimalarials, of whom 14,644 (88.5%) were diagnosed with RA and 1894 (11.5%) with SLE, were included in the study. The median number of 90-day follow-up windows for all patients was 33 (mean, 35). A cumulative 22% antimalarial adherence rate was noted for all 90-day windows of exposure among patients with RA and SLE, with 59% categorized as discontinuation, and 19% as nonadherence. Over the mean follow-up time of 9 years, 2174 (13.2%) patients experienced an incident cardiovascular event. A majority of those events were associated with antimalarial discontinuation (n=1394). The adjusted hazard ratio (aHR) for incident cardiovascular events for antimalarial adherence relative to discontinuation was 0.72 (95% CI, 0.64-0.81), and 1.01 (95% CI, 0.90-1.14) for nonadherence relative to discontinuation. Estimates were not statistically different between the antimalarial discontinuation and nonadherence groups. Patients with RA and SLE who did adhere to antimalarial therapy were found to have a 29% lower risk for incident cardiovascular events, compared against those who did not adhere to treatment (aHR, 0.71; 95% CI, 0.61-0.82). When stratified according to specific cardiovascular event, antimalarial adherence was found to have a comparable risk reduction, with a 38% lower risk for MI (aHR, 0.62; 95% CI, 0.51-0.75), a 55% lower risk for stroke (aHR, 0.45; 95% CI, 0.36-0.58), and a 35% lower risk for VTE (aHR, 0.65; 95% CI, 0.46-0.93), when compared with nonadherence. A secondary analysis using an 80% cut-off for antimalarial adherence was shown to have similar findings; the aHRs for incident cardiovascular events for antimalarial adherence compared with nonadherence was 0.74 (95% CI, 0.66-0.82) and 1.09 (95% CI, 0.96-1.24), respectively. Of note, stratified analyses by disease type and sex did not show any effect modification, except for age group. The relative risk reduction of incident cardiovascular events among patients aged at least 65 years was significantly greater compared with those aged less than 65 years, when comparing antimalarial adherence with nonadherence (risk reduction, 41% vs 17%; P =.02). This study was limited by a lack of data on reasons for antimalarial nonadherence and discontinuation, as well as unmeasured lifestyle factors contributing to adherence. Additional risk factors for cardiovascular events, such as disease activity, body mass index, smoking, and alcohol consumption were unavailable in the data. The study authors concluded, “The protective effect of antimalarial was found to be lost when adhering to less than 90% of the prescribed doses, and a greater degree of protection was observed in older patients. Therefore, enhancing medication adherence should be incorporated into appropriate screening strategies targeting high-risk populations (e.g., assessment for antiphospholipid antibodies in SLE) and encouraging compliance from patients to nonpharmacologic measures.” References: Hoque, MR, Avina-Zubeita JA, Lacaille D. Antimalarial adherence and risk of cardiovascular events in rheumatoid arthritis and systemic lupus erythematosus patients: a population-based study. Arthritis Care Res (Hoboken). Published online September 10, 2023. doi:10.1002/acr.25233.

The following is a summary of “Plasma Serotonin and Cardiovascular Outcomes in Chronic Kidney Disease,” published in the August 2023 issue of Cardiology by Edmonston et al. Researchers performed a prospective study to determine the relationship between platelet-poor plasma serotonin levels and cardiovascular outcomes in patients with chronic kidney disease. They assessed the association between plasma serotonin levels (categorized as undetectable, intermediate, and high ≥20 ng/mL) and echocardiographic findings, cardiovascular outcomes including heart failure hospitalization, atherosclerotic cardiovascular disease events (ASCVD), and mortality in 1,114 participants from the prospective CRIC (Chronic Renal Insufficiency Cohort) Study. The impact of selective serotonin reuptake inhibitors on the serotonin-outcome relationship was also assessed. The results showed plasma serotonin levels exhibited an inverse relationship with estimated glomerular filtration rate while directly correlating with blood pressure. Elevated plasma serotonin levels corresponded with left ventricular hypertrophy (adjusted odds ratio: 2.74 [95% CI: 1.11–7.41]). Conversely, having undetectable plasma serotonin levels correlated with the highest risk of heart failure (adjusted hazard ratio [HR]: 2.26 [95% CI: 1.40–3.66]) and ASCVD events (adjusted HR: 1.96 [95% CI: 1.15–3.32]). Investigators concluded low and high plasma serotonin levels were associated with ASCVD risk in people with chronic kidney disease. Source: ahajournals.org/doi/full/10.1161/JAHA.123.029785

Semaglutide, a weight loss drug recently linked to key cardiovascular benefits for obese and overweight patients, may have a limited impact due to its significant price tag. At least, that’s the perspective of Airfinity, a disease forecasting company that uses predictive health data to anticipate how certain developments could impact the market at large. Back in August, Novo Nordisk, which sells subcutaneous treatments of semaglutide 2.4 mg under the brand name Wegovy, shared initial findings from the SELECT trial that suggested the medication could help obese and overweight patients reduce their risk of a major adverse cardiovascular event (MACE) by up to 20%. Weeks later, researchers at ESC Congress 2023, the annual meeting of the European Society of Cardiology, presented research on semaglutide’s potential to improve outcomes among certain heart failure patients. The team at Airfinity focused on those early SELECT trial results, estimating that 63 patients would need to be treated with semaglutide over a three-year period to prevent one heart attack, stroke or cardiovascular death. Because the current Wegovy price tag is $1,350 per month, researchers wrote that the cost of treating those 63 patients would be approximately $1.1 million—and that’s even after considerable rebates were included.

The “Cardiovascular Monitoring Devices Market” Research Report gives a comprehensive overview of the market, highlighting the key market growth trends, new opportunities, threats, and drivers. Also given is the market’s CAGR value. Market research on Cardiovascular Monitoring Devices provides qualitative and quantitative analysis of company profiles, development updates, industry size, and market share across all over geographical regions. The report also provides a comprehensive primary analysis of the market with an emphasis on the supply chain, segmentation, application types, key players, and industry sectors of the market. It offers a thorough grasp of the entire ecosystem, together with in-depth knowledge of important market categories and the impact they have on particular regions. Ask for Sample Report Market Analysis and Insights: Global Cardiovascular Monitoring Devices Market The global Cardiovascular Monitoring Devices market size was valued at USD 24459.88 million in 2021 and is expected to expand at a CAGR of 4.03 percentage during the forecast period, reaching USD 30994.47 million by 2027.Cardiovascular Monitoring Devices usually refers to continuous or intermittent monitoring of cardiac activity and assessment of the patient’s condition relative to his or her heart rhythm. Major Players in Cardiovascular Monitoring Devices market are: Medtronic PLC FUKUDA DENSHI Co., Ltd., Philips Healthcare LivaNova PLC Welch Allyn, Inc. St. Jude Medical, Inc. Siemens Healthcare Boston Scientific Corporation GE Healthcare BIOTRONIK SE and Co. KG Get a Sample Copy of the report: https://www.absolutereports.com/enquiry/request-sample/21439187 Cardiovascular Monitoring Devices Market by Types: ECG systems Holter Monitors Event Monitors Others Cardiovascular Monitoring Devices Market by Applications: Hospital Clinic Others Cardiovascular Monitoring Devices Market Key Points: Define, describe and forecast Cardiovascular Monitoring Devices product market by type, application, end user and region. Provide enterprise external environment analysis and PEST analysis. Provide strategies for company to deal with the impact of COVID-19. Provide market dynamic analysis, including market driving factors, market development constraints. Provide market entry strategy analysis for new players or players who are ready to enter the market, including market segment definition, client analysis, distribution model, product messaging and positioning, and price strategy analysis. Keep up with international market trends and provide analysis of the impact of the COVID-19 epidemic on major regions of the world. Analyze the market opportunities of stakeholders and provide market leaders with details of the competitive landscape. To Understand How Covid-19 Impact Is Covered in This Report – https://www.absolutereports.com/enquiry/request-covid19/21439187 Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historical data and forecast : United States Europe China Japan India Southeast Asia Latin America Middle East and Africa Outline Chapter 1 mainly defines the market scope and introduces the macro overview of the industry, with an executive summary of different market segments ((by type, application, region, etc.), including the definition, market size, and trend of each market segment. Chapter 2 provides a qualitative analysis of the current status and future trends of the market. Industry Entry Barriers, market drivers, market challenges, emerging markets, consumer preference analysis, together with the impact of the COVID-19 outbreak will all be thoroughly explained. Chapter 3 analyzes the current competitive situation of the market by providing data regarding the players, including their sales volume and revenue with corresponding market shares, price and gross margin. In addition, information about market concentration ratio, mergers, acquisitions, and expansion plans will also be covered. Chapter 4 focuses on the regional market, presenting detailed data (i.e., sales volume, revenue, price, gross margin) of the most representative regions and countries in the world. Chapter 5 provides the analysis of various market segments according to product types, covering sales volume, revenue along with market share and growth rate, plus the price analysis of each type. Chapter 6 shows the breakdown data of different applications, including the consumption and revenue with market share and growth rate, with the aim of helping the readers to take a close-up look at the downstream market. Chapter 7 provides a combination of quantitative and qualitative analyses of the market size and development trends in the next five years. The forecast information of the whole, as well as the breakdown market, offers the readers a chance to look into the future of the industry. Chapter 8 is the analysis of the whole market industrial chain, covering key raw materials suppliers and price analysis, manufacturing cost structure analysis, alternative product analysis, also providing information on major distributors, downstream buyers, and the impact of COVID-19 pandemic. Chapter 9 shares a list of the key players in the market, together with their basic information, product profiles, market performance (i.e., sales volume, price, revenue, gross margin), recent development, SWOT analysis, etc. Chapter 10 is the conclusion of the report which helps the readers to sum up the main findings and points. Chapter 11 introduces the market research methods and data sources. Major Questions Addressed in the Report: What is the anticipated growth rate of the Cardiovascular Monitoring Devices market and what factors are influencing this growth in the next years? What is the market’s perception and adoption rate of the various kinds of Cardiovascular Monitoring Devices? How are government initiatives and regulatory measures influencing the expansion of the Cardiovascular Monitoring Devices market? What are the top 5 competitors’ market shares, and how are they projected to change over the next few years? What new developments and technology are there in the Cardiovascular Monitoring Devices market, and how are they changing the business environment? What impact do macroeconomic variables like GDP, inflation, and exchange rates have on the Cardiovascular Monitoring Devices market? What are the supply chain and logistical issues the participants in the Cardiovascular Monitoring Devices market are dealing with? How are the dynamics of the Cardiovascular Monitoring Devices market being impacted by shifting customer behaviour and preferences? What potential dangers and pitfalls could accompany investing in the Cardiovascular Monitoring Devices market, and how can they be avoided? Inquire or Share Your Questions If Any before the Purchasing This Report – https://www.absolutereports.com/enquiry/pre-order-enquiry/21439187 Detailed TOC of Global Cardiovascular Monitoring Devices Industry Research Report 1 Cardiovascular Monitoring Devices Market Overview 1.1 Product

Bookmark 1. In this cross-sectional study, a higher Mediterranean diet (MedDiet) score was associated with improvements in several cardiovascular outcomes, including cardiovascular risk score, blood pressure, and body mass index (BMI) in adults. 2. However, women demonstrated a significant association between MedDiet scores and multiple cardiovascular outcomes, while men only showed a significant association between MedDiet scores and lower BMI. Evidence Rating Level: 2 (Good) Cardiovascular diseases affect a large proportion of the aging population and have high morbidity and mortality. Diet is an important component of managing cardiovascular disease risks, and studies have suggested that the Mediterranean diet (MedDiet) is beneficial in improving cardiovascular risk, particularly in men. This study sought to further evaluate the effect of MedDiet adherence on cardiovascular risk factors in adult men and women. This cross-sectional study included 533 adult participants living in the UK (60% women) from the PREVENT Dementia cohort. Participants were included in the PREVENT cohort if they consented to participation and did not have dementia at baseline. Participants were excluded from analyses if they had missing exposure, outcome, and covariate data. Baseline data was collected from the PREVENT dataset. MedDiet adherence was assessed using 3 different scores: the Mediterranean Diet Adherence Screener (MEDAS) score, the MEDAS continuous score, and the Pyramid score. Scores were determined based on self-reported food consumption of 175 foods over the last 2-3 months using the Scottish Collaborative Group Good Frequency Questionnaire (SCG-FFQ). Cardiovascular outcomes included the cardiovascular risk score using the Framingham Risk Score and the QRisk3 scoring method, blood pressure, body mass index (BMI), waist-to-hip ratio (WHR), fasting blood glucose level, triglycerides, and cholesterol level. The primary outcome was the association between MedDiet adherence and cardiovascular risk. The results demonstrated that higher MedDiet scores were associated with lower blood pressure, BMI, and cardiovascular risk scores. Women demonstrated significant associations between MedDiet scores and lower blood pressure, BMI, and glycemia, while men only demonstrated a significant association between MedDiet scores and lower BMI. However, this study was limited by the self-reported nature of MedDiet adherence, which may have introduced social desirability bias and the lack of diversity in the study participants, which limited its generalizability. Nonetheless, the results suggested that MedDiet adherence may be associated with an improved cardiovascular risk profile, especially in adult women. Click to read the study in Nutrition, Metabolism, and Cardiovascular Diseases Image: PD ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.